HU6
Rivus Pharmaceuticals Unveils Promising Phase 2a Results for HU6 in Obesity-Related Heart Failure Patients
HU6, Rivus Pharmaceuticals, obesity-related heart failure, fat-selective weight loss, controlled metabolic accelerators (CMAs), mitochondrial uncoupling, cardiometabolic diseases.
Rivus Advances in Obesity-Related Heart Failure with Mid-Stage Success of HU6
Rivus Pharmaceuticals, HU6, obesity-related heart failure, Phase IIa HuMAIN trial, controlled metabolic accelerator, muscle-preserving weight loss